Corvus Pharmaceuticals, Inc. (CRVS) Operating income 2016–2025
Corvus Pharmaceuticals, Inc. (CRVS) annual operating income history from SEC filings — each fiscal year as reported.
-$43.0MFY2025 · since FY2016: -$37.0M → -$43.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$43.0M | -56.0% |
| FY2024 | -$27.5M | -17.7% |
| FY2023 | -$23.4M | +28.1% |
| FY2022 | -$32.6M | +15.7% |
| FY2021 | -$38.6M | +11.7% |
| FY2020 | -$43.8M | +10.4% |
| FY2019 | -$48.9M | +0.7% |
| FY2018 | -$49.2M | +12.9% |
| FY2017 | -$56.5M | -52.9% |
| FY2016 | -$37.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More CRVS financial trends
CRVS RevenueCRVS Net incomeCRVS Net marginCRVS Gross profitCRVS Gross marginCRVS Operating marginCRVS Operating cash flowCRVS Free cash flowCRVS Capital expendituresCRVS Return on equityCRVS Stock buybacksCRVS Dividends paidCRVS Total assetsCRVS Total liabilitiesCRVS Shareholders’ equityCRVS overview →